Soligenix, Inc. announced the appointment of Marco Maria Brughera, DVM, Global Head of the Rare Disease Franchise for Sigma-Tau SpA, to its Board of Directors. Since January 2011, Dr. Brughera has held several positions for the Sigma-Tau Group, including Corporate Research and Development Managing Director of Sigma-Tau SpA, President of Sigma-Tau Research and Board Member of Sigma-Tau Pharmaceuticals. He currently serves on the Board of Gentium SpA.